AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 67 min read$CURLF

Curaleaf Holdings, Inc. (CURLF): Results of Operations and Financial Condition

Curaleaf Holdings, Inc. (CURLF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q226-exx994xearningsrelease.htm EX-99.1 Document Curaleaf Reports Second Quarter 2026 Results: Continued Growth, Margin Strength, and Profitability Second quarter 2026 net revenue of $340 million Second quarter 2026 International revenue of $51 million Second quarter 20

Original reporting
SEC EDGAR 8-K
Published Aug 6, 2026, 1:51 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 10:35 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$CURLF
Bullish
medium confidence
Mentioned
$CURLF
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CURLFBullishMed
01

Why it matters

The filing is a primary earnings disclosure with specific revenue, margin, profitability, and balance sheet figures, which can drive immediate re-pricing and revisions to near-term estimates.

02

Market read

Q2 2026 earnings release with hard numbers (revenue, gross margin, net income, adjusted EBITDA) plus operational expansion details (retail footprint, brand launch, international ownership) that can influence trading and estimate revisions.

03

What to watch

The excerpt notes a DEA registration application and international approvals, but without quantified timing or impact; traders may overreact to operational headlines versus cash flow durability.

Relevance 7/10Novelty 8/10Timing: filed pre-market/early trading today after Q2 close, Aug 5, 2026

Background

SEC 8-K Item 2.02 includes Curaleaf’s Q2 2026 results and selected operational updates, including retail footprint changes and international ownership/approvals.

Company-level read

Ticker impact

$CURLFBullishMedium confidence
Context

Curaleaf filed an 8-K with Q2 2026 results showing $340.1M net revenue (+10% YoY) and $70.1M adjusted EBITDA.

Expected impact

Likely supportive for the stock on growth and gross margin, but expect some pushback from the YoY adjusted EBITDA margin compression.

Evidence & confidence

The filing provides concrete quarterly financials (revenue, gross margin, net income, adjusted EBITDA) plus balance sheet cash and debt, which traders typically use to re-rate near-term fundamentals. However, the excerpt does not include full guidance or forward-looking targets, limiting conviction on magnitude/direction.

Market effects

Sector

Provides a datapoint on cannabis operator profitability and international growth momentum, useful for read-across to peers’ margin expectations.

Regional

Florida retail footprint expansion and international segment growth may reinforce investor focus on state-level execution and cross-border scaling.

Global

International revenue growth (26% YoY) and full ownership of a German subsidiary support the narrative of expanding non-US earnings streams.

Counterpoint

What could challenge this read

Adjusted EBITDA margin fell 120 bps YoY, suggesting cost pressure or mix effects that could cap multiple expansion despite revenue growth.

Key entities

  • company
    Curaleaf Holdings, Inc.

    OTCQX-listed cannabis operator reporting Q2 2026 results in an SEC 8-K.

  • subsidiary
    Four20 Pharma

    German subsidiary where Curaleaf completed buyout of remaining 45% equity interest to reach 100% ownership.

  • regulator
    DEA

    Curaleaf states it applied to register its medical cultivation, processing, and dispensing locations.

Read at source← All news

Related articles

AUG 5
$CURLFMedAI 8/10

Curaleaf Reports Second Quarter 2026 Results: Continued Growth, Margin Strength, and Profitability

Curaleaf Holdings reported Q2 2026 net revenue of $340.1 million, up 10% year over year, with gross margin at 50% and net income from continuing operations of $12.5 million. Adjusted EBITDA was $70.1 million. International revenue was $51 million. The company ended the quarter with $107.0 million cash and said it expanded retail and completed its Four20 Pharma buyout.

montrealgazette.com7 min
JUN 3
$CURLFMedAI 8/10

Curaleaf Confirms Effective Date of Reverse Stock Split

Curaleaf Holdings confirmed its previously announced 1-for-3 reverse stock split of subordinate voting shares will take effect June 5, 2026. Shares will keep trading on the TSX under “CURA” with a new CUSIP (23126M300). The company has 698,731,895 shares outstanding, expected to fall to about 232,910,632; no fractional shares will be issued. A concurrent 1-for-3 consolidation of multiple voting shares will also occur.

prnewswire.com2 min
AUG 8
$NNNMed

NNN REIT Q2 Earnings Call Highlights

NNN REIT (NYSE:NNN) reported Q2 earnings call highlights. It cut its full-year bad-debt outlook to about 40 bps from 60 bps, kept second-half credit-loss assumptions, and raised the annual disposition guidance midpoint by $10 million to $140 million. In Q2 it invested $290M in 89 properties, occupancy rose to 99.1%, and it declared a $0.62/share dividend.

yahoo.com6 min
AUG 8
$NTRMed

Nutrien Q2 Earnings Call Highlights

Nutrien’s CEO Ken Seitz said the company used automation to mine 53% of ore tons in the first half, exceeding its 2024 target range. Nutrien maintained 2026 potash shipment guidance of 74-77 million tons and 2026 nitrogen sales-volume guidance of 9.2-9.7 million tons. Q2 nitrogen adjusted EBITDA was $635 million. The company cut 2026 capex guidance to $1.95B-$2.05B and raised share repurchases to about $75M/month.

yahoo.com6 min
AUG 8
$NVGSMed

Navigator Q2 Earnings Call Highlights

Navigator Holdings (NYSE:NVGS) reported Q2 updates. Its 2026 all-in cash breakeven rose to $21,990 per vessel per day from $21,230, citing the pending sale of eight Unigas Pool vessels. Morgan’s Point ethylene terminal set a record 374,278 tonnes; Navigator’s equity income was $7.1m. It sold Navigator Pegasus for $30.5m and expects Unigas sales net proceeds about $129m and book gains $65m-$70m. Dividend $0.07/share; Q3 TCE and volumes expected to moderate.

yahoo.com6 min
AUG 8
$NUVBMed

Nuvation Bio Q2 Earnings Call Highlights

Nuvation Bio (NUVB) reported Q2 call highlights for IBTROZI in ROS1-positive lung cancer, citing TRUST-I results in TKI-naive patients with a 90% objective response rate and 50-month median response duration and progression-free survival. The company said first-line ROS1 TKI use rose nearly 20% through May 2026. It also updated safusidenib Phase II J201 (52% ORR, 79% 36-month PFS) and outlined Phase III/G307 and G209 studies. Cash was $661M after a June convertible notes offering.

yahoo.com6 min